The FDA approval expands the use of marstacimab-hncq (Hympavzi; Pfizer Inc.) for routine prophylaxis to prevent or reduce bleeding episodes in additional pediatric and inhibitor-positive hemophilia A and B...
The FDA has approved concizumab-mtci, a daily subcutaneous treatment to reduce bleeding for patients with hemophilia who have clotting factor inhibitors.
The FDA has approved a novel therapy for patients with hemophilia A or B without inhibitors. Clinical trials showed it significantly reduces bleeding episodes by targeting a new protein in the blood...
After clinical trials demonstrated its efficacy, the US Food and Drug Administration approved a new treatment option for patients with hemophilia A who have Factor VIII inhibitors.
Primary care practitioners should be aware of 3 new FDA approvals that may be useful when treating patients with meningitis B, hemophilia A, and non-valvular atrial fibrillation.
